The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Key challenges in treating patients with t(11;14) multiple myeloma with BCL2 inhibitors
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, discusses the challenges which remain in the treatment of patients with t(11;14) relapsed/refractory (R/R) multiple myeloma (MM). Dr Kaufman notes that the BCL2 inhibitor venetoclax alone and combined with dexamethasone, daratumumab, or carfilzomib has shown promising efficacy in the t(11;14) population. However, the major challenge is that venetoclax is not approved for myeloma, and recent Phase III data mean that approval will not occur in the near future. Dr Kaufman remains hopeful and highlights that the second-generation BCL2 inhibitors currently in development may provide a novel option for targeting BCL2 in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
